In a phase 3 randomised withdrawal trial, children and adolescents (6–18 years) with Tourette syndrome who responded to open-label ecopipam had lower relapse risk if continued on ecopipam vs placebo (HR 0.47; n=90). Adult effect was non-significant (n=14).
RCTn = 216
Gilbert et al. Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial